Evidence map›Paper›PMID 39002130›Full record

ArticleCell reports2024

Crimean-Congo hemorrhagic fever survivors elicit protective non-neutralizing antibodies that target 11 overlapping regions on glycoprotein GP38.

Olivia S Shin, Stephanie R Monticelli, Christy K Hjorth, Vladlena Hornet, Michael Doyle, Dafna Abelson, Ana I Kuehne, Albert Wang, Russell R Bakken, Akaash K Mishra and 17 more

Abstract read
In one paragraph

Article in Cell reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

Olivia S ShinAdimab, LLC, Lebanon, NH 03766, USA.
Stephanie R MonticelliU.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA; Geneva Foundation, Tacoma, WA 98042, USA.
Christy K HjorthDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.
Vladlena HornetAdimab, LLC, Lebanon, NH 03766, USA.
Michael DoyleAdimab, LLC, Lebanon, NH 03766, USA.
Dafna AbelsonMapp Biopharmaceutical, Inc., San Diego, CA 92121, USA.
Ana I KuehneU.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.
Albert WangDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Russell R BakkenU.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.
Akaash K MishraDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.
Marissa MiddlecampMapp Biopharmaceutical, Inc., San Diego, CA 92121, USA.
Elizabeth ChampneyAdimab, LLC, Lebanon, NH 03766, USA.
Lauran StuartMapp Biopharmaceutical, Inc., San Diego, CA 92121, USA.
Daniel P MaurerAdimab, LLC, Lebanon, NH 03766, USA.
Jiannan LiAdimab, LLC, Lebanon, NH 03766, USA.
Jacob BerriganDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Jennifer BarajasMapp Biopharmaceutical, Inc., San Diego, CA 92121, USA.
Stephen BalinandiUganda Virus Research Institute, Entebbe, Uganda.
Julius J LutwamaUganda Virus Research Institute, Entebbe, Uganda.
Leslie LobelDepartment of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
Larry ZeitlinMapp Biopharmaceutical, Inc., San Diego, CA 92121, USA.
Laura M WalkerAdimab, LLC, Lebanon, NH 03766, USA.
John M DyeU.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.
Kartik ChandranDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Andrew S HerbertU.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA. Electronic address: andrew.s.herbert4.civ@health.mil.
Noel T PauliAdimab, LLC, Lebanon, NH 03766, USA. Electronic address: noel.pauli@adimab.com.
Jason S McLellanDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA. Electronic address: jmclellan@austin.utexas.edu.

Funding

Prometheus: A Platform for Rapid Development of Human Antibody-based Therapeutics and Prophylactics against Emerging Viral ThreatsU19AI142777 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI CHANDRAN, KARTIK · 2019 to 2023
$21.9M
Structure-based Vaccine Design for CCHFVR01AI152246 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI CHANDRAN, KARTIK, MCLELLAN, JASON SCOTT · 2020 to 2024
$2.2M
NIAID NIH HHS R01 AI152246NIAID NIH HHS U19 AI142777
6 · The paper itself

Abstract

Crimean-Congo hemorrhagic fever virus can cause lethal disease in humans yet there are no approved medical countermeasures. Viral glycoprotein GP38, exclusive to Nairoviridae, is a target of protective antibodies and is a key antigen in preclinical vaccine candidates. Here, we isolate 188 GP38-specific antibodies from human survivors of infection. Competition experiments show that these antibodies bind across 5 distinct antigenic sites, encompassing 11 overlapping regions. Additionally, we show structures of GP38 bound with 9 of these antibodies targeting different antigenic sites. Although these GP38-specific antibodies are non-neutralizing, several display protective efficacy equal to or better than murine antibody 13G8 in two highly stringent rodent models of infection. Together, these data expand our understanding regarding this important viral protein and may inform the development of broadly effective CCHFV antibody therapeutics.

Indexed as

Antibodies, ViralHemorrhagic Fever, CrimeanHemorrhagic Fever Virus, Crimean-CongoAnimalsAntibodies, NeutralizingEpitopesFemaleGlycoproteinsHumansMiceSurvivorsAntibodies, NeutralizingAntibodies, ViralEpitopesGlycoproteinsantibody therapeuticsCCHFVCP: ImmunologyCrimean-Congo hemorrhagic fever virusGP38human monoclonal antibodyNairoviridaetickborneviral glycoprotein

Identifiers

PMID39002130
PMCPMC11346345

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.